ASX:RHT

Stock Analysis Report

Executive Summary

Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide.


Snowflake Analysis

Flawless balance sheet with weak fundamentals.

Share Price & News

How has Resonance Health's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: RHT's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

23.8%

RHT

8.7%

AU Medical Equipment

1.1%

AU Market


1 Year Return

44.4%

RHT

14.1%

AU Medical Equipment

-18.9%

AU Market

Return vs Industry: RHT exceeded the Australian Medical Equipment industry which returned 8.8% over the past year.

Return vs Market: RHT exceeded the Australian Market which returned -19.4% over the past year.


Shareholder returns

RHTIndustryMarket
7 Day23.8%8.7%1.1%
30 Day-10.3%-13.2%-20.8%
90 Day-48.0%-13.5%-25.0%
1 Year44.4%44.4%16.1%14.1%-15.2%-18.9%
3 Year465.2%465.2%35.4%29.0%-2.6%-16.0%
5 Year319.4%319.4%79.5%64.0%7.9%-16.4%

Price Volatility Vs. Market

How volatile is Resonance Health's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Resonance Health undervalued compared to its fair value and its price relative to the market?

8.51x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: RHT (A$0.11) is trading above our estimate of fair value (A$0.02)

Significantly Below Fair Value: RHT is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: RHT is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: RHT is unprofitable, so we can't compare its PE Ratio to the Australian market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate RHT's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: RHT is overvalued based on its PB Ratio (7.2x) compared to the AU Medical Equipment industry average (3.2x).


Next Steps

Future Growth

How is Resonance Health forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

39.5%

Forecasted Healthcare industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Resonance Health has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has Resonance Health performed over the past 5 years?

13.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: RHT is currently unprofitable.

Growing Profit Margin: RHT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: RHT is unprofitable, but has reduced losses over the past 5 years at a rate of 13.6% per year.

Accelerating Growth: Unable to compare RHT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: RHT is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (14.7%).


Return on Equity

High ROE: RHT has a negative Return on Equity (-12.03%), as it is currently unprofitable.


Next Steps

Financial Health

How is Resonance Health's financial position?


Financial Position Analysis

Short Term Liabilities: RHT's short term assets (A$4.6M) exceed its short term liabilities (A$722.5K).

Long Term Liabilities: RHT's short term assets (A$4.6M) exceed its long term liabilities (A$88.4K).


Debt to Equity History and Analysis

Debt Level: RHT is debt free.

Reducing Debt: RHT has not had any debt for past 5 years.


Balance Sheet

Inventory Level: RHT has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if RHT's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: RHT has been profitable on average in the past, therefore cash runway is not a concern.

Forecast Cash Runway: RHT has been profitable on average in the past, therefore cash runway is not a concern.


Next Steps

Dividend

What is Resonance Health's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate RHT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate RHT's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if RHT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if RHT's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of RHT's dividend in 3 years as they are not forecast to pay a notable one for the Australian market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

2.6yrs

Average management tenure


CEO

Alison Laws

2.17s

Tenure

AU$196,068

Compensation

Ms. Alison Laws has been the Chief Executive Officer at Resonance Health Limited since February 2018. Ms. Laws joined Resonance Health in 2016. She served as Global Account Manager for Resonance Health. Sh ...


CEO Compensation Analysis

Compensation vs Market: Alison's total compensation ($USD120.28K) is below average for companies of similar size in the Australian market ($USD246.06K).

Compensation vs Earnings: Alison's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Alison Laws
Chief Executive Officer2.17yrsAU$196.07kno data
Agha Pervez
CFO & Company Secretary2.42yrsAU$197.85k0.023% A$11.0k
Celine Royet
Quality Assurance & Regulatory Affairs Manager4.83yrsAU$111.22kno data
Jason Loveridge
Corporate Advisor2.83yrsAU$40.00kno data

2.6yrs

Average Tenure

Experienced Management: RHT's management team is considered experienced (2.6 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Martin Peter Blake
Independent & Non-Executive Chairman9.33yrsAU$60.00k1.46% A$711.1k
Mitchell Wells
Non Executive Director2.17yrsAU$112.50k0.14% A$66.0k
Simon Panton
Independent Director10.5yrsAU$40.00k16.57% A$8.1m
Travis Baroni
Non-Executive Director3.42yrsAU$40.00k0.11% A$55.0k

6.4yrs

Average Tenure

Experienced Board: RHT's board of directors are considered experienced (6.4 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 2.7%.


Top Shareholders

Company Information

Resonance Health Limited's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Resonance Health Limited
  • Ticker: RHT
  • Exchange: ASX
  • Founded:
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: AU$48.815m
  • Shares outstanding: 443.77m
  • Website: https://www.resonancehealth.com

Location

  • Resonance Health Limited
  • 141 Burswood Road
  • Ground Floor
  • Burswood
  • Western Australia
  • 6100
  • Australia

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
RHTASX (Australian Securities Exchange)YesOrdinary SharesAUAUDApr 1994
RHTCHIA (Chi-X Australia)YesOrdinary SharesAUAUDApr 1994

Biography

Resonance Health Limited, a healthcare company, develops and delivers non-invasive medical imaging software and services worldwide. Its flagship product is FerriScan, a non-invasive liver diagnostic technology used for the measurement of liver iron concentration. The company also offers Cardiac T2, a dual analysis service with FerriScan to provide information regarding body iron stores; HepaFat-Scan, a magnetic resonance imaging (MRI) based tool for the measurement of volumetric liver fat fraction; and Bone Marrow R2-MRI for the assessment of iron levels in the bone marrow. It also provides imaging core laboratory and support services for clinical trials, including clinical measurement, as well as project and data management services, such as reporting, administration, and support. The company serves clinicians for the diagnosis and management of human diseases; and pharmaceutical companies for their clinical trials. Resonance Health Limited is headquartered in Burswood, Australia. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/04/02 10:32
End of Day Share Price2020/04/02 00:00
Earnings2019/12/31
Annual Earnings2019/06/30


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.